search
Back to results

The Sensitivity and Specificity of CardioSimFFRct Analysis Software on Coronary Artery Stenosis

Primary Purpose

Coronary Stenosis

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
FFR and FFRCT
Sponsored by
CCRF Inc., Beijing, China
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Coronary Stenosis

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Subjects that participate in this study must fulfill all the following criteria:

General inclusion criteria:

  • Age ≥18 years and ≤ 80 years;
  • Subject providing written informed consent;
  • After the researcher assessed the suspected presence of coronary artery stenosis, coronary angiography and CCTA examination were proposed.

Angiographic inclusion criteria:

  • CCTA inspection should be performed on instruments with at least 64 multidetector rows;
  • CCTA images are clear and readable;
  • The diameter of coronary artery lesion stenosis was measured by CCTA image with 30%-90%;
  • The reference vessel diameter of coronary stenosis was ≥2.5mm by CCTA imaging.

Exclusion Criteria:

If subjects fulfill any of below criteria, this subject shall be exclude from this study.

General exclusion criteria:

  • Pregnant and breast-feeding women;
  • Previous ST-segment elevation myocardial infarction 30 days before CCTA examination, and a history of non-ST-segment elevation myocardial infarction 7 days before CCTA examination;
  • Prior Coronary Artery Bypass Graft(CABG),Pacemaker, Implantable Cardioverter Defibrillator(ICD), Artificial Valve Implantation;
  • Hypertrophic obstructive cardiomyopathy;
  • Heart failure(NYHA≥III or Left Ventricular Ejection Fraction(LVEF)< 40%);
  • Atrial fibrillation, supraventricular tachycardia, ventricular tachycardia and other arrhythmias;
  • Body mass index >35kg/m2;
  • Serum creatinine >178µmol/L or 2mg/dl;
  • Allergies or contraindications to contrast agents are known;
  • Subject who received Nicorandil within 2 weeks prior to invasive FFR examination;
  • Any other conditions that are not suitable for the study.

Angiographic exclusion criteria:

  • The quality of CT imaging is not good enough to extract coronary blood vessel trees;
  • Visual measurement of coronary lesion diameter stenosis > 90% by CCTA imaging;
  • The target lesions were diffuse lesions, and the lesion length was ≥ 30mm (visual measurement);
  • There were ≥ 2 stenosis lesions in the target vessel;
  • Stent implantation in the target vessel;
  • Lesions involving aneurysms or myocardial Bridges;
  • The target vessel is very tortuous and it is difficult to predict the passage of the pressure guide wire.
  • Left main disease;
  • Patients with acute coronary syndrome after CCTA examination and before invasive FFR examination;
  • Severe calcification(i.e Diffuse calcification ,Local or segmental calcification)

Sites / Locations

  • The First Affiliated Hospital of Zhengzhou University
  • Wuhan Asia Heart Hospital
  • Nanjing First Hospital
  • The Second Hospital of Jilin University
  • The Second Hospital of Dalian University
  • General Hospital of Northern Theater Command
  • Tianjin Chest Hospital
  • The First Affiliated Hospital Zhejiang University School of Medicine

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Patients diagnosed with Coronary Artery Disease(CAD)by CCTA

Arm Description

Patients admitted to hospital with the diagnosed of CAD by CCTA and who accept to participate to the study will undergo the invasive coronary angiography, fractional flow reserve (FFR) will be measured during the invasive coronary angiography.Outcome measures were comparing FFRct to FFR.

Outcomes

Primary Outcome Measures

Sensitivity and specificity (subject level) of FFRCT
Sensitivity and specificity (subject level) for predicting the functional significance of coronary artery stenosis using CT-Derived Fractional Flow Reserve Score Analysis Software.

Secondary Outcome Measures

AUC between FFRCT vs. FFR
Comparing the Area Under Curve(AUC) between FFRct and CCTA to determine the Functional significance of coronary stenosis.
Sensitivity and Specificity between FFRCT vs. FFR
Comparing the Sensitivity and Specificity which at the lesion level between FFRct and CCTA
Accuracy (lesion level and subject level) between FFRCT vs. FFR
Comparing the Accuracy which at the lesion level and subject level between FFRct and CCTA
Positive Predictive Value (PPV) between FFRCT vs. FFR
Comparing the positive predictive value (PPV) between FFRct and CCTA
Negative Predictive Value (NPV) between FFRCT vs. FFR
Comparing the negative predictive value (NPV) between FFRct and CCTA

Full Information

First Posted
July 30, 2020
Last Updated
September 29, 2020
Sponsor
CCRF Inc., Beijing, China
Collaborators
Shengshi Technology, Co., Ltd, Hangzhou, China
search

1. Study Identification

Unique Protocol Identification Number
NCT04569669
Brief Title
The Sensitivity and Specificity of CardioSimFFRct Analysis Software on Coronary Artery Stenosis
Official Title
A Clinical Trial on the Diagnostic Performance Based on CT-Derived Fractional Flow Reserve Score Analysis Software for Coronary Artery Stenosis
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Unknown status
Study Start Date
October 9, 2020 (Anticipated)
Primary Completion Date
October 9, 2021 (Anticipated)
Study Completion Date
March 9, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CCRF Inc., Beijing, China
Collaborators
Shengshi Technology, Co., Ltd, Hangzhou, China

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The device involved in this trail is a diagnostic software with a Prospective, Multicenter, Self Controlled design. FFRCT diagnostic performance was calculated by CardioSimFFRct Analysis software, and the diagnostic accuracy, sensitivity, specificity, positive predictive value and negative predictive performance of FFRCT for myocardial ischemia were calculated per-patient level and per-vessel level with invasive FFR value as gold standard.
Detailed Description
The present study is a single arm, open label, prospective trial. Measurement of FFR during invasive cardiac catheterization represents the "gold standard" for assessment of the hemodynamic significance of coronary artery lesions. As we know, the major disadvantage of FFR is that it has to be measured invasively. CardioSimFFRct Analysis software is a non-invasive method to determine FFR which computes the hemodynamic significance of Coronary Artery Disease (FFRCT) from coronary computed tomography angiography(CCTA)data of the subject by using computational fluid dynamics.The FFR derived from FFR-CT will be compared with invasive FFR as gold standard.Moreover CardioSimFFRct also simplifies the coronary artery into a one-dimensional piping model, omits grid engineering, and greatly reduces the complexity of pretreatment.Based on the pressure loss along the pipe flow and the local pressure loss, a fast method for FFR calculation in engineering is proposed. The calculation time can be reduced to several minutes. FFRct from CardioSimFFRct Analysis software is mainly based on CCTA images to image the coronary arteries. Through three-dimensional reconstruction of the coronary arteries and computational fluid Dynamics (CFD) technology, the simulation of blood flow in the blood vessels is realized to extract the coronary blood flow reserve score (FFR).FFRct has the following characteristics such as the FFR value can be measured noninvasively, without additional damage to patients, avoiding the risks brought by invasive surgery, and the side effects brought by drugs during invasive surgery.FFRct can realize the examination quickly, save the time of doctors' coronary functional assessment, and simplify the process of coronary functional assessment.It also has the function of three-dimensional reconstruction of blood vessels, which makes it convenient for users to view the whole structure of coronary arteries and make artificial correction.The results of FFRct have high repeatability and are easy for users to evaluate.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Stenosis

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
325 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Patients diagnosed with Coronary Artery Disease(CAD)by CCTA
Arm Type
Experimental
Arm Description
Patients admitted to hospital with the diagnosed of CAD by CCTA and who accept to participate to the study will undergo the invasive coronary angiography, fractional flow reserve (FFR) will be measured during the invasive coronary angiography.Outcome measures were comparing FFRct to FFR.
Intervention Type
Diagnostic Test
Intervention Name(s)
FFR and FFRCT
Intervention Description
All the patients will undergo computed coronary tomography angiography to analysis FFRCT . Then FFR will be measured during invasive cardiac catheterization.
Primary Outcome Measure Information:
Title
Sensitivity and specificity (subject level) of FFRCT
Description
Sensitivity and specificity (subject level) for predicting the functional significance of coronary artery stenosis using CT-Derived Fractional Flow Reserve Score Analysis Software.
Time Frame
Measurement at Procedure/Baseline Visit
Secondary Outcome Measure Information:
Title
AUC between FFRCT vs. FFR
Description
Comparing the Area Under Curve(AUC) between FFRct and CCTA to determine the Functional significance of coronary stenosis.
Time Frame
Measurement at Procedure/Baseline Visit
Title
Sensitivity and Specificity between FFRCT vs. FFR
Description
Comparing the Sensitivity and Specificity which at the lesion level between FFRct and CCTA
Time Frame
Measurement at Procedure/Baseline Visit
Title
Accuracy (lesion level and subject level) between FFRCT vs. FFR
Description
Comparing the Accuracy which at the lesion level and subject level between FFRct and CCTA
Time Frame
Measurement at Procedure/Baseline Visit
Title
Positive Predictive Value (PPV) between FFRCT vs. FFR
Description
Comparing the positive predictive value (PPV) between FFRct and CCTA
Time Frame
Measurement at Procedure/Baseline Visit
Title
Negative Predictive Value (NPV) between FFRCT vs. FFR
Description
Comparing the negative predictive value (NPV) between FFRct and CCTA
Time Frame
Measurement at Procedure/Baseline Visit

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects that participate in this study must fulfill all the following criteria: General inclusion criteria: Age ≥18 years and ≤ 80 years; Subject providing written informed consent; After the researcher assessed the suspected presence of coronary artery stenosis, coronary angiography and CCTA examination were proposed. Angiographic inclusion criteria: CCTA inspection should be performed on instruments with at least 64 multidetector rows; CCTA images are clear and readable; The diameter of coronary artery lesion stenosis was measured by CCTA image with 30%-90%; The reference vessel diameter of coronary stenosis was ≥2.5mm by CCTA imaging. Exclusion Criteria: If subjects fulfill any of below criteria, this subject shall be exclude from this study. General exclusion criteria: Pregnant and breast-feeding women; Previous ST-segment elevation myocardial infarction 30 days before CCTA examination, and a history of non-ST-segment elevation myocardial infarction 7 days before CCTA examination; Prior Coronary Artery Bypass Graft(CABG),Pacemaker, Implantable Cardioverter Defibrillator(ICD), Artificial Valve Implantation; Hypertrophic obstructive cardiomyopathy; Heart failure(NYHA≥III or Left Ventricular Ejection Fraction(LVEF)< 40%); Atrial fibrillation, supraventricular tachycardia, ventricular tachycardia and other arrhythmias; Body mass index >35kg/m2; Serum creatinine >178µmol/L or 2mg/dl; Allergies or contraindications to contrast agents are known; Subject who received Nicorandil within 2 weeks prior to invasive FFR examination; Any other conditions that are not suitable for the study. Angiographic exclusion criteria: The quality of CT imaging is not good enough to extract coronary blood vessel trees; Visual measurement of coronary lesion diameter stenosis > 90% by CCTA imaging; The target lesions were diffuse lesions, and the lesion length was ≥ 30mm (visual measurement); There were ≥ 2 stenosis lesions in the target vessel; Stent implantation in the target vessel; Lesions involving aneurysms or myocardial Bridges; The target vessel is very tortuous and it is difficult to predict the passage of the pressure guide wire. Left main disease; Patients with acute coronary syndrome after CCTA examination and before invasive FFR examination; Severe calcification(i.e Diffuse calcification ,Local or segmental calcification)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yaling Han, professor
Phone
+86-024-28851120
Email
hanyaling@263.net
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yaling Han, professor
Organizational Affiliation
The General Hospital of Northern Theater Command
Official's Role
Principal Investigator
Facility Information:
Facility Name
The First Affiliated Hospital of Zhengzhou University
City
Zhengzhou
State/Province
Henan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chunguang Qiu, professor
Phone
+8613803898806‬
Email
qcg123@163.com
Facility Name
Wuhan Asia Heart Hospital
City
Wuhan
State/Province
Hubei
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xi Su, professor
Phone
+86-027-65796888
Email
yaxin_suxi@163.com
Facility Name
Nanjing First Hospital
City
Nanjing
State/Province
Jiangsu
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shaoliang Chen, professor
Phone
+86-025-52271351
Email
chmengx@126.com
Facility Name
The Second Hospital of Jilin University
City
Changchun
State/Province
Jilin
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bin Liu, professor
Phone
+86-0431-88796739
Email
liubin3333@vip.sina.com
Facility Name
The Second Hospital of Dalian University
City
Dalian
State/Province
Liaoning
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peng Qu, professor
Phone
+86-0411-84671291
Ext
3098
Email
qupeng777@aliyun.com
Facility Name
General Hospital of Northern Theater Command
City
Shenyang
State/Province
Liaoning
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yaling Han, professor
Phone
+86-024-28851120
Email
hanyaling@263.net
Facility Name
Tianjin Chest Hospital
City
Tianjing
State/Province
Tianjing
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hongliang Cong, professor
Phone
+86-022-88185003
Email
hongliangcong@126.com
Facility Name
The First Affiliated Hospital Zhejiang University School of Medicine
City
Hangzhou
State/Province
Zhejiang
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jianhua Zhu, professor
Phone
+8613958039959
Email
zjh-john2015@163.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Sensitivity and Specificity of CardioSimFFRct Analysis Software on Coronary Artery Stenosis

We'll reach out to this number within 24 hrs